Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Thiomersal-free FluAS25 adjuvanted vaccine (GSK576389A)
Thiomersal-free FluAS25 adjuvanted vaccine · 1 trial · 1 indication
Titers were expressed as Geometric Mean Titers (GMTs). The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.
| Arm | Type | Description |
|---|---|---|
| Thiomersal-free FluAS25 adjuvanted vaccine group | EXPERIMENTAL | Subjects received 1 dose of thiomersal-free FluAS25 adjuvanted vaccine |
| Thiomersal reduced FluAS25 adjuvanted vaccine group | EXPERIMENTAL | Subjects received 1 dose of thiomersal reduced FluAS25 adjuvanted vaccine |
| Name | Type | Description |
|---|---|---|
| Thiomersal-free FluAS25 adjuvanted vaccine (GSK576389A) | BIOLOGICAL | Intramuscular administration, 1 dose |
| Thiomersal reduced FluAS25 adjuvanted vaccine (GSK576389A) | BIOLOGICAL | Intramuscular administration, 1 dose |
Inclusion Criteria: * Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. * A male or female 65 years of age or older at the time of vaccination. * Written informed consent obtained from the subject. * Free of a...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE1 | Cell-based Trivalent Split Influenza Virus Vaccine, Egg-based Trivalent Split Influenza Virus Vaccine |
The Thiomersal-free FluAS25 adjuvanted vaccine is an investigational influenza vaccine developed by GSK plc under the code GSK576389A. It is formulated without thiomersal and includes an adjuvant, and it was studied in older adults aged 65 years and above for the prevention of influenza.
It is being developed for the prevention of influenza. The vaccine was evaluated in a Phase 2 study in adults aged 65 years and older, a population at higher risk of influenza complications. It is an investigational product and has not been approved for use.
GSK plc, which trades under the ticker GSK, is the developer of the Thiomersal-free FluAS25 adjuvanted vaccine, also known as GSK576389A. The vaccine was studied under GSK Biologicals, the company's vaccines business.
The Thiomersal-free FluAS25 adjuvanted vaccine is in Phase 2 development. One Phase 2 trial has been completed, and no trials are currently active. It is an investigational vaccine and is not approved for any indication.
The vaccine was studied in NCT00633074, a Phase 2 non-inferiority trial comparing different formulations of GSK576389A. The trial enrolled 720 participants aged 65 years and older in Estonia, was randomized, double-blind, and controlled, and has been completed.
Yes. GSK576389A is the development code for the Thiomersal-free FluAS25 adjuvanted vaccine. Both names refer to the same GSK influenza vaccine candidate, which was evaluated in a completed Phase 2 trial in older adults.